Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia

Rita Assi, Guillermo Garcia-Manero, Farhad Ravandi, Gautam Borthakur, Naval G. Daver, Elias Jabbour, Jan Burger, Zeev Estrov, Courtney D. Dinardo, Yesid Alvarado, Stephany Hendrickson, Alessandra Ferrajoli, William Wierda, Jorge Cortes, Hagop Kantarjian, Tapan M. Kadia

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Background: The immune-mediated destruction of hematopoietic stem cells is implicated in the pathophysiology of aplastic anemia (AA). Immunosuppressive therapy (IST) using antithymocyte globulin and cyclosporine is successful in this setting. Eltrombopag is active in patients with refractory AA, presumably by increasing the bone marrow progenitors. Methods: This phase 2 trial initially was designed to evaluate standard IST in newly diagnosed patients with severe AA and later was amended to add eltrombopag to simultaneously address immune destruction and stem cell depletion. The primary outcome was the overall response rate (ORR) at 3 months and 6 months. Results: A total of 38 patients were enrolled: 17 (45%) received IST alone and 21 (55%) received additional eltrombopag. The ORR was 74%. Patients receiving IST plus eltrombopag had a similar ORR (76% vs 71%; P =.72), complete remission rate (38% vs 29%; P =.73), and median time to response (84 days vs 57 days; P =.30) compared with those receiving IST alone. The 2-year overall survival rate in the IST group was 91% compared with 82% for those patients treated with IST plus eltrombopag (P =.82). No cumulative toxicities were noted after the addition of eltrombopag. Conclusions: The addition of eltrombopag to standard IST was well tolerated and resulted in similar responses.

Original languageEnglish (US)
Pages (from-to)4192-4201
Number of pages10
JournalCancer
Volume124
Issue number21
DOIs
Publication statusPublished - Nov 1 2018
Externally publishedYes

    Fingerprint

Keywords

  • aplastic anemia
  • cyclosporine
  • eltrombopag
  • horse antithymocyte globulin
  • stem cells

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Assi, R., Garcia-Manero, G., Ravandi, F., Borthakur, G., Daver, N. G., Jabbour, E., ... Kadia, T. M. (2018). Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia. Cancer, 124(21), 4192-4201. https://doi.org/10.1002/cncr.31658